Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 353 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Majority of Patients With Cancer Are Willing To Be Vaccinated Against... February 2, 2021 What Are Social Determinants of Health and How Do They Affect... July 22, 2021 ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... June 6, 2023 Increased Risk of Cancer in Early Life Among Individuals with Autism... April 28, 2022 Load more HOT NEWS Fisioterapeutas en oncología What to Know About Getting Access to New Cancer Advances Presented... Children with Acute Lymphoblastic Leukemia Can Skip Radiation to the Brain Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles
